Editor’s Note: This interview was conducted at #Bio2018. Please pardon the background noise.
Barry Greene, President of Alnylam, provides RNA interference (RNAi) and the first ever new class of innovative medicines to potentially enter the market this year. Specifically, Patisiran is an investigational RNAi therapeutic targeting transthyretin (TTR) in development for the treatment of hereditary ATTR amyloidosis (hATTR amyloidosis).
Patisiran is the only investigational medicine in our pipeline that utilizes a lipid nanoparticle (LNP) formulation and is administered via intravenous infusion.